Latest News

 Filter by Provider

These are excellent companies, but only one can be the better investment in this comparison.

Remitly is scaling up and expanding margins.

There is something for everyone in this excellent group of stocks.

Accelerating revenue growth is exciting Palantir stock investors.

The cloud services growth is accelerating.

The move might surprise you.

Record equity free cash flow of $327 million signals strong operational momentum.

Nvidia, Micron, and SK Hynix all look like big winners after SpaceX's first earnings call.

This insider disposition was tied to RSU vesting obligations, not discretionary trading.

World Cup drove record revenue and advertising gains, while Tubi hit 110 million users.

Revenue guidance raised to $4.3B–$4.5B as non-DARZALEX products drive half of growth.

The shares were sold under a Rule 10b5-1 trading plan to cover tax withholding from RSU vesting.

electroCore (NASDAQ:ECOR) reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales lifted results. The company raised its full-year revenue outlook to growth of m

Dropbox (NASDAQ:DBX) reported second-quarter 2026 revenue growth and raised its full-year profitability and free-cash-flow outlook, as executives said continued improvements in its core file-sync-and-share business are supporting a return to sustainable growth. Revenue rose 0.9% year over year to $

Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following positive Phase III results in major depressive disorder reported in June. Chief Executive Officer Rob Bar

Denali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer’s disease programs into clinical development. Chief Execu

CVRx (NASDAQ:CVRX) reported second-quarter revenue growth and an improved gross margin, but lowered its full-year outlook as sales-force turnover, slower productivity ramps and reimbursement challenges with a large Medicare Advantage payer are expected to weigh on results in the second half of 2026.

CryoPort (NASDAQ:CYRX) reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million. Chief Executive Officer Jerrell Shelton said revenue momentum continue

Cytokinetics (NASDAQ:CYTK) reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten in non-obstructive hypertrophic cardiomyopathy, or nHCM. Chief Executive Officer Robert Blum said t

CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv

For years, a 29-year-old says he did everything he thought he was supposed to do. He earned a college degree, landed a work-from-home job and climbed into a controller role. His paycheck kept growing, but his life